These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
903 related articles for article (PubMed ID: 31301056)
1. Evaluation of Safety and Efficacy of Growth Hormone Therapy by IGF-1 Z Score in Children with Short Stature. Liu HJ; Wang LH; Chen L Adv Ther; 2019 Sep; 36(9):2374-2383. PubMed ID: 31301056 [TBL] [Abstract][Full Text] [Related]
2. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment. Soliman A; Rogol AD; Elsiddig S; Khalil A; Alaaraj N; Alyafie F; Ahmed H; Elawwa A J Pediatr Endocrinol Metab; 2021 Oct; 34(10):1263-1271. PubMed ID: 34291621 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial]. Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383 [TBL] [Abstract][Full Text] [Related]
4. Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study. Soliman AT; Elawwa A; Itani M; Jour C; De Sanctis V Acta Biomed; 2019 Sep; 90(8-S):43-51. PubMed ID: 31544806 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children. Hou L; Liang Y; Wu W; Lin HH; Luo XP; Ying YQ Growth Horm IGF Res; 2020; 53-54():101331. PubMed ID: 32777706 [TBL] [Abstract][Full Text] [Related]
6. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. Cohen P; Germak J; Rogol AD; Weng W; Kappelgaard AM; Rosenfeld RG; J Clin Endocrinol Metab; 2010 May; 95(5):2089-98. PubMed ID: 20207829 [TBL] [Abstract][Full Text] [Related]
7. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy. Ballerini MG; Braslavsky D; Scaglia PA; Keselman A; Rodríguez ME; Martínez A; Freire AV; Domené HM; Jasper HG; Bergadá I; Ropelato MG Horm Res Paediatr; 2017; 88(5):354-363. PubMed ID: 28926833 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of recombinant human growth hormone in treating Chinese children with idiopathic short stature. Ying YQ; Hou L; Liang Y; Wu W; Luo XP Growth Horm IGF Res; 2018; 42-43():80-85. PubMed ID: 30343148 [TBL] [Abstract][Full Text] [Related]
9. Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Dutch Growth Hormone Working Group. Wit JM; Boersma B; de Muinck Keizer-Schrama SM; Nienhuis HE; Oostdijk W; Otten BJ; Delemarre-Van de Waal HA; Reeser M; Waelkens JJ; Rikken B Clin Endocrinol (Oxf); 1995 Apr; 42(4):365-72. PubMed ID: 7750190 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy of different doses of recombinant human growth hormone in the treatment of short stature in children born small for gestational age]. Qie D; Yang F Zhongguo Dang Dai Er Ke Za Zhi; 2016 Mar; 18(3):247-53. PubMed ID: 26975824 [TBL] [Abstract][Full Text] [Related]
11. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center. Al Shaikh A; Daftardar H; Alghamdi AA; Jamjoom M; Awidah S; Ahmed ME; Soliman AT Acta Biomed; 2020 Mar; 91(1):29-40. PubMed ID: 32191651 [TBL] [Abstract][Full Text] [Related]
12. Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations. Cohen P; Weng W; Rogol AD; Rosenfeld RG; Kappelgaard AM; Germak J Clin Endocrinol (Oxf); 2014 Jul; 81(1):71-6. PubMed ID: 24428305 [TBL] [Abstract][Full Text] [Related]
13. Etiology of short stature in Indian children and an assessment of the growth hormone-insulin-like growth factor axis in children with idiopathic short stature. Kumar A; Pal A; Kalaivani M; Gupta N; Jain V J Pediatr Endocrinol Metab; 2018 Sep; 31(9):1009-1017. PubMed ID: 30130251 [TBL] [Abstract][Full Text] [Related]
14. Plasma levels of insulin-like binding protein-2 in prepubertal short children and its diagnostic value in the evaluation of growth hormone deficiency. van Doorn J; Ringeling AM; Rikken B; van Buul-Offers SC Horm Res; 2001; 55(3):147-54. PubMed ID: 11549877 [TBL] [Abstract][Full Text] [Related]
15. Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database. Kim M; Kim EY; Kim EY; So CH; Kim CJ PLoS One; 2021; 16(11):e0259287. PubMed ID: 34723984 [TBL] [Abstract][Full Text] [Related]
16. Growth hormone therapy does not alter the insulin-like growth factor-I/insulin-like growth factor binding protein-3 molar ratio in growth hormone-deficient children. Scirè G; Del Bianco C; Spadoni GL; Cianfarani S J Endocrinol Invest; 2008 Feb; 31(2):153-8. PubMed ID: 18362507 [TBL] [Abstract][Full Text] [Related]
17. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Tillmann V; Patel L; Gill MS; Whatmore AJ; Price DA; Kibirige MS; Wales JK; Clayton PE Clin Endocrinol (Oxf); 2000 Sep; 53(3):329-36. PubMed ID: 10971450 [TBL] [Abstract][Full Text] [Related]
18. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment. Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543 [TBL] [Abstract][Full Text] [Related]
19. National Cooperative Growth Study substudy VI: the clinical utility of growth-hormone-binding protein, insulin-like growth factor I, and insulin-like growth factor-binding protein 3 measurements. Attie KM; Julius JR; Stoppani C; Rundle AC J Pediatr; 1997 Jul; 131(1 Pt 2):S56-60. PubMed ID: 9255230 [TBL] [Abstract][Full Text] [Related]
20. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age. Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]